Ozempic (semaglutide)

Ozempic (semaglutide) is a prescription medicine for the treatment of adult patients with type 2 diabetes mellitus.

Ozempic is approved for this indication in the USA, EU, Canada, Japan, and Australia.

What is Ozempic (semaglutide) for?

Ozempic is a medicine prescribed for the treatment of adult patients with type 2 diabetes mellitus. Although in recent years Ozempic has been often prescribed “off-label” for weight loss, it is not currently approved for this indication.

Ozempic (semaglutide) is available as a single-patient-use pen for subcutaneous injection in the following strengths:

• 2 mg/3 mL, delivering 0.25 mg or 0.5 mg per injection;
• 4 mg/3 mL, delivering 1 mg per injection;
• 8 mg/3 mL, delivering 2 mg per injection.

How does Ozempic (semaglutide) work?

The active ingredient in Ozempic, semaglutide, is a GLP-1 receptor antagonist. It acts the same way as GLP-1 (a hormone produced in the gut). By increasing the amount of insulin released by the pancreas in response to food, semaglutide helps control blood glucose levels.

Where has Ozempic (semaglutide) been approved?

Ozempic (semaglutide) is currently approved in the USA, EU, Canada, Japan, and Australia for the treatment of type 2 diabetes.

Ozempic is not approved anywhere for use as a weight loss medication.